Kaptopril tablets

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

captopril

Доступна с:

KRKA d.d.

код АТС:

C09AA01

ИНН (Международная Имя):

captopril

дозировка:

25mg

Фармацевтическая форма:

tablets

Штук в упаковке:

(20/2x10/) in blister

Тип рецепта:

Prescription

Статус Авторизация:

Registered

Дата Авторизация:

2018-10-03

тонкая брошюра

I(RI(I-\
KAPTOPRIL tablets 25 mg
VOL:
1; P: 79/269
1.3.1
SPC,
Labeling and Package Leaflet
JIUCToK-RKJla,UbIUl
(O,UUOBPCMCHJlOHHCTpYKl.\lU1no
MC,UIIUHHCKOMY"pIIMCHeHUIO
JleKapCTBeHlIoro
CpcllcTBa)
KAnTOnPlfJI
Ta6J1eTKIl
12,5
Mr,
25
Mr,
50
Mr
KaIlTonpl1JJ
TOllTOBoe
Ha3BaHHC
KAf1TOTIPI1J1
06lUaIJ
xapaKTepllcTuKa
_Me:JICoYllopooHoe_
_HenameHmOBaHHoe_
_HG3BalWe_
KanTOlIpHJI
(Captopril)
_Onucallue_
_Ta6nemKlt_
_12,5_
_.HZ:_
Kpyrnhle,
cnerKa
,[IBOllKoBhmYKJlhle
Ta6JIeTl(J1 6eJIoro
UBeTa co CKoweHHhlMI1
KPaJIJlUI.
_Ta6nemKlI_
25
_M2:_
KpyrJll:,le
Ta6J1CTKH 6eJloro
UBeTa
co
CKoweHHhlMH
KpaJIMH H HaCeqKOH Ha
O,UHOI{cTopoHe.
_Ta6.~e111KZI_
_50_
_J1!tz:_
Kpyrnhle,
cnerKa
.D:BollKoBhmYKJlhle
Ta6neTKI1
6enoro
llBeTa
co
CKOllleHHhlMH
KpaJIJIIH I{
HaCeq}(OM Ha O,UHOHcTopoHe.
COCT3S
O,llHa m6JTeTJapMaKoTepanCSTll'IeCKaH
rpynna
II KO,UKJlaCClIljJlIKal.\l1II JleKapCTBCHJlOrO cpe,UCTB3
HHrlt6HTOP
ru;lHoTeH3HH-npeBpall.laIOll.lero
q)epMeHTa (ATIapMaKOJlOTlI'leCKlle
CBoiicTB3
_([)apMaKOOllllaJItllK(l_
KamonpHfl
HHm6HpyeT
aHrHOTeH3HH-npeBpall.lalOll.lHH
Hblii
3

Прочитать полный документ

Характеристики продукта

PI_Text042404_2
– Updated:
Page 1 of 16
1.
NAME OF THE MEDICINAL PRODUCT
Kaptopril 25 mg tablets
Kaptopril 50 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 25 mg or 50 mg captopril.
Excipient:
25 mg tablets
50 mg tablets
lactose
47.50 mg/tablet
95.00 mg/tablet
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
The tablets of 25 mg are white, round, slightly biconvex tablets with
bevelled edges and scored on one
side. The score line is not intended for breaking the tablet.
The tablets of 50 mg are white, round, slightly biconvex tablets with
bevelled edges and a score on one
side. The score line is not intended is not intended for breaking the
tablet.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
-
Hypertension:
The management of mild to moderate hypertension. In severe
hypertension it should be used
where standard therapy is ineffective or inappropriate.
-
Congestive heart failure:
Captopril is indicated for the treatment of congestive heart failure.
The drug should be used
together with diuretics, and when appropriate, digitalis and
beta-blockers. In patients on doses
of over 100 mg daily plus or minus a diuretic, in those with severe
renal impairment or those
with severe congestive heart failure use of captopril should be under
specialist supervision.
-
Myocardial infarction:
Short-term (4 weeks) treatment: Captopril is indicated in any
clinically stable patient within
the first 24 hours of an infarction. Long-term prevention of
symptomatic heart failure:
Captopril is indicated in clinically stable patients with asymptomatic
and symptomatic left
ventricular dysfunction (ejection fraction < 40%) following myocardial
infarction to improve
survival, delay the onset of symptomatic heart failure, reduce
hospitalisations for heart failure
and reduce recurrent myocardial infarction and coronary
revascularisation procedures.
Before starting therapy, cardiac function should be determined by
radionuclide
ventriculography or echocardiography.
-
Type I Diabe